About
Committees
Get Involved
Clinical Trials
Career Center
Events
Patient Advocacy
KNOW Your State Legislative Tool
Membership
Join MOASC
Renew Your Membership
Sponsors
Newsletter
Healthcare News from PR Newswire
909-985-9061
JOIN OR RENEW NOW
About
Committees
Get Involved
Clinical Trials
Career Center
Events
Patient Advocacy
KNOW Your State Legislative Tool
Membership
Join MOASC
Renew Your Membership
Sponsors
Newsletter
Healthcare News from PR Newswire
A Phase II Open Label Trial of Neo-Adjuvant Abemaciclib with Fulvestrant in Patients Who Develop Localized Recurrence While on Adjuvant Endocrine Therapy with Molecular Evidence of Endocrine Resistance
On November 30th, 2021
No comments have been posted yet.
No comments have been posted yet.